Compensatory effects of the human nucleoside transporters on the response to nucleoside-derived drugs in breast cancer MCF7 cells

Biochemical Pharmacology

Volumn 75, Issue 3, 2008, Pages 639-648

  Cano Soldado, Pedro ^a,c   Molina Arcas, Míriam ^a,c   Algueró, Berta ^a   Larráyoz, Ignacio ^b   Lostao, M Pilar ^b   Grandas, Anna ^a   Casado, F Javier ^a,c   Pastor Anglada, Marçal ^a,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

5 DFUR; Breast cancer; hCNT1; Inhibitor; Nucleoside analogues; Nucleoside transport

Indexed keywords

CONCENTRATIVE NUCLEOSIDE TRANSPORTER 1; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 2; DOXIFLURIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; NUCLEOSIDE TRANSPORTER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; DEOXYCYTIDINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE TRANSPORT PROTEINS;

EID: 38049058351     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.10.005     Document Type: Article

References (31)

1. Gray J.H., Owen R.P., and Giacomini K.M. The concentrative nucleoside transporter family, SLC28. Pflugers Arch 447 (2004) 728-734
2. Baldwin S.A., Beal P.R., Yao S.Y., King A.E., Cass C.E., and Young J.D. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 447 (2004) 735-743
3. Marce S., Molina-Arcas M., Villamor N., Casado F.J., Campo E., Pastor-Anglada M., et al. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 91 (2006) 895-902
4. Molina-Arcas M., Bellosillo B., Casado F.J., Montserrat E., Gil J., Colomer D., et al. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood 101 (2003) 2328-2334
5. Molina-Arcas M., Marce S., Villamor N., Huber-Ruano I., Casado F.J., Bellosillo B., et al. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia 19 (2005) 64-68
6. Gloeckner-Hofmann K., Guillen-Gomez E., Schmidtgen C., Porstmann R., Ziegler R., Stoss O., et al. Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer. Oncology 70 (2006) 238-244
7. Giovannetti E., Del Tacca M., Mey V., Funel N., Nannizzi S., Ricci S., et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66 (2006) 3928-3935
8. Spratlin J., Sangha R., Glubrecht D., Dabbagh L., Young J.D., Dumontet C., et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10 (2004) 6956-6961
9. Kho P.S., Wang Z., Zhuang L., Li Y., Chew J.L., Ng H.H., et al. p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem 279 (2004) 21183-21192
10. Hernandez-Vargas H., Ballestar E., Carmona-Saez P., von Kobbe C., Banon-Rodriguez I., Esteller M., et al. Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. Int J Cancer 119 (2006) 1164-1175
11. Molina-Arcas M., Moreno-Bueno G., Cano-Soldado P., Hernandez-Vargas H., Casado F.J., Palacios J., et al. Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5′-DFUR in breast cancer MCF7 cells. Biochem Pharmacol 72 (2006) 1646-1656
12. Farre X., Guillen-Gomez E., Sanchez L., Hardisson D., Plaza Y., Lloberas J., et al. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer 112 (2004) 959-966
13. Mata J.F., Garcia-Manteiga J.M., Lostao M.P., Fernandez-Veledo S., Guillen-Gomez E., Larrayoz I.M., et al. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol Pharmacol 59 (2001) 1542-1548
14. Fernandez-Veledo S., Valdes R., Wallenius V., Casado F.J., and Pastor-Anglada M. Up-regulation of the high-affinity pyrimidine-preferring nucleoside transporter concentrative nucleoside transporter 1 by tumor necrosis factor-alpha and interleukin-6 in liver parenchymal cells. J Hepatol 41 (2004) 538-544
15. Lostao M.P., Mata J.F., Larrayoz I.M., Inzillo S.M., Casado F.J., and Pastor-Anglada M. Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes. FEBS Lett 481 (2000) 137-140
16. Larrayoz I.M., Casado F.J., Pastor-Anglada M., and Lostao M.P. Electrophysiological characterization of the human Na(+)/nucleoside cotransporter 1 (hCNT1) and role of adenosine on hCNT1 function. J Biol Chem 279 (2004) 8999-9007
17. Cano-Soldado P., Lorrayoz I.M., Molina-Arcas M., Casado F.J., Martinez-Picado J., Lostao M.P., et al. Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1). Antivir Ther 9 (2004) 993-1002
18. Chang C., Swaan P.W., Ngo L.Y., Lum P.Y., Patil S.D., and Unadkat J.D. Molecular requirements of the human nucleoside transporters hCNT1, hCNT2, and hENT1. Mol Pharmacol 65 (2004) 558-570
19. Troester M.A., Hoadley K.A., Sorlie T., Herbert B.S., Borresen-Dale A.L., Lonning P.E., et al. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 64 (2004) 4218-4226
20. Oguri T., Achiwa H., Muramatsu H., Ozasa H., Sato S., Shimizu S., et al. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett 256 (2007) 112-119
21. Chow L., Lai R., Dabbagh L., Belch A., Young J.D., Cass C.E., et al. Analysis of human equilibrative nucleoside transporter 1 (hENT1) protein in non-Hodgkin's lymphoma by immunohistochemistry. Mod Pathol 18 (2005) 558-564
22. Mackey J.R., Jennings L.L., Clarke M.L., Santos C.L., Dabbagh L., Vsianska M., et al. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin Cancer Res 8 (2002) 110-116
23. Reiman T., Clarke M.L., Dabbagh L., Vsianska M., Coupland R.W., Belch A.R., et al. Differential expression of human equilibrative nucleoside transporter 1 (hENT1) protein in the Reed-Sternberg cells of Hodgkin's disease. Leuk Lymphoma 43 (2002) 1435-1440
24. Ngo L.Y., Patil S.D., and Unadkat J.D. Ontogenic and longitudinal activity of Na(+)-nucleoside transporters in the human intestine. Am J Physiol Gastrointest Liver Physiol 280 (2001) G475-G481
25. Mangravite L.M., Badagnani I., and Giacomini K.M. Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. Eur J Pharmacol 479 (2003) 269-281
26. Casado F.J., Lostao M.P., Aymerich I., Larrayoz I.M., Duflot S., Rodriguez-Mulero S., et al. Nucleoside transporters in absorptive epithelia. J Physiol Biochem 58 (2002) 207-216
27. Fernandez-Veledo S., Jover R., Casado F.J., Gomez-Lechon M.J., and Pastor-Anglada M. Transcription factors involved in the expression of SLC28 genes in human liver parenchymal cells. Biochem Biophys Res Commun 353 (2007) 381-388
28. Duflot S., Calvo M., Casado F.J., Enrich C., and Pastor-Anglada M. Concentrative nucleoside transporter (rCNT1) is targeted to the apical membrane through the hepatic transcytotic pathway. Exp Cell Res 281 (2002) 77-85
29. Fernandez-Veledo S., Huber-Ruano I., Aymerich I., Duflot S., Casado F.J., and Pastor-Anglada M. Bile acids alter the subcellular localization of CNT2 (concentrative nucleoside cotransporter) and increase CNT2-related transport activity in liver parenchymal cells. Biochem J 395 (2006) 337-344
30. Galmarini C.M., Thomas X., Calvo F., Rousselot P., Rabilloud M., El Jaffari A., et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 117 (2002) 860-868
31. Reiman T., Graham K.A., Wong J., Belch A.R., Coupland R., Young J., et al. Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study. Leukemia 16 (2002) 1886-1887